EDAP Technomed gets investigational device exemption (IDE) for Sonolith 4000+
This article was originally published in Clinica
EDAP Technomed will begin a five-centre US trial of its Sonolith 4000+ lithotripsy device following IDE approval from the US FDA. The non-surgical device is used for the treatment of kidney stone disease through an electroconductive process which completely fragments the stones without the need for anaesthesia. Sonolith also offers digital slit-scan X-ray which delivers a digital image of the stone and minimises radiation exposure.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.